Convatec expands support for people living with advanced Parkinson´s disease with its infusion set technology

11 January 2024

Convatec’s Neria™Guard infusion device is used for continuous subcutaneous infusion of a number of drugs for patients on infusion pump.

Convatec’s infusion set technology continues to expand into new therapy areas beyond diabetes, further supporting people with Parkinson’s disease who depend on subcutaneous drug delivery.

Convatec Group Plc (LSE:CTEC), a FTSE 100 global medical devices and technologies company focused on solutions for the management of chronic conditions, is pleased to announce a significant step forward for people living with advanced Parkinson´s disease.

The worldwide population living with Parkinson´s, a disease leading to disability and affecting quality of life^1,2, is estimated to be 10 million³. Consistent with our ‘forever caring’ promise, we are pleased to announce the expanded use of our technology further for people living with Parkinson´s disease with the use of our Neria™Guard subcutaneous infusion set for apomorphine and Foslevodopa-foscarbidopa.

This is a significant step towards providing more subcutaneous drug delivery options for certain groups of patients where this treatment is an option aligned with their healthcare professional. Convatec has been able to achieve this milestone by partnering with pharma companies that are launching their drugs together with Neria™Guard infusion set.

Neria™Guard is an all-in-one infusion set with fully automatic insertion at the touch of a button⁴ that can make it easier to use especially for those with dexterity issues⁵. The set connects to a pump on one end and the user’s infusion site on the other end. The retractable needle can provide increased comfort* during insertion of the soft cannula⁵ and can help prevent accidental needle-stick incidents⁴. Neria™Guard's easy and intuitive insertion technique⁴ protects against insertion technique errors⁴ and can encourage independence in patients’ everyday lives in agreement with their healthcare professional.⁵

*compared to a steel needle.

Convatec’s Neria™Guard infusion set will now also be used with Foslevodopa-foscarbidopa in selected EU countries.

Kjersti Grimsrud, President & Chief Operating Officer, Infusion Care said, “We are pleased to be able to support people living with chronic disease in more markets and give more treatment options using our innovative Neria™Guard infusion set. This demonstrates the strength of Convatec’s leadership in subcutaneous infusion solutions as we continue to provide innovation to people living with chronic diseases beyond diabetes”.

Contacts

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care, and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Group revenues in 2022 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com

For information about Neria™Guard, please refer to the instructions for use that come with the product.

References:

^1. Fasano, A., Fung, V.S.C., Lopiano, L. et al. (2019). Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurology, 19 (1), 50.

^2. Barone, P., Antonini, A., and Colosimo et al. (2009). The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society, 24 (11), 1641–1649.

^3. https://www.parkinsonseurope.org/about-parkinsons/what-is-parkinsons/; Accessed November 30, 2023.

^4. Convatec Data on File, Unomedical A/S, 2023. (D012-002912)

^5. Hillman E. (2020). Examining the use of sharp-free subcutaneous infusion devices with apomorphine. British Journal of Neuroscience Nursing, 16 (4), 5.